Zhejiang Wecome Pharmaceutical (300878.SZ): Huangjia Ruangan Granules Approved to Initiate Phase III Clinical Trial for Liver Fibrosis in Chronic Hepatitis B

Zhejiang Wecome Pharmaceutical (300878.SZ) announced that the company recently received the "Drug Clinical Trial Supplementary Application Approval Notice" for Huangjia Ruangan Granules issued upon approval by the National Medical Products Administration. Upon review, the clinical trial application for Huangjia Ruangan Granules complies with the relevant requirements for drug registration. On the basis of further improving the clinical trial protocol, it is agreed to initiate a Phase III clinical trial for liver fibrosis in chronic hepatitis B.